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Abstract
Background: Minocycline provides neurovascular protection reducing acute cerebral injury. However, it is unclear
whether minocycline is effective in females. We tested minocycline in both sexes and aged animals using a novel
embolic stroke model in mice that closely mimics acute thromboembolic stroke in humans.
Methods: Five groups of mice were subjected to thromboembolic stroke: adult males, aged males, adult females,
aged females, and adult ovariectomized females. They were treated with phosphate saline (vehicle) or minocycline
(6 mg/kg) immediately after stroke onset. Behavioral outcomes, infarct volumes and cerebral blood flow were
assessed. The effect of minocycline on expression and activity of MMP-9 was analyzed.
Results: The model resulted in reproducible infarct in the experimental groups. As expected, adult females were
significantly more resistant to cerebral ischemic injury than males. This advantage was abolished by aging and
ovariectomy. Minocycline significantly reduced the infarct volume (P < 0.0001) and also improved neurologic score
(P < 0.0001) in all groups. Moreover, minocycline treatment significantly reduced mortality at 24 hours post stroke
(P = 0.037) for aged mice (25% versus 54%). Stroke up-regulated MMP-9 level in the brain, and acute minocycline
treatment reduced its expression in both genders (P < 0.0001).
Conclusion: In a thromboembolic stroke model minocycline is neuroprotective irrespective of mouse sex and age.
Keywords: thromboembolic stroke, animal model, neuroprotection, minocycline, sex, MMP-9
Introduction
Interest in sex differences during acute stroke is an area
of growing interest. A consistent finding in rodent mod-
els of cerebral ischemia is that young females have smal-
ler infarct sizes and better outcomes than young male
rodents [1]. This female protection is lost after ovariect-
omy. However, the sex difference in stroke is only pre-
sent when the brain is reperfused; in permanent
occlusion the sex difference vanishes [2]. Moreover, in
older rodents, the sex difference seen in younger animals
is lost [3]. Reproductively senescent older female and
male mice have similar infarct sizes after 2 hours of
ischemia and 22 hours of reperfusion [4].
T h ee f f e c to fs e xo ns t r o k eo u t c o m em a ya l s ob eh o r -
mone independent [3]. Recent studies suggest the
existence of sex-divergent cell death pathways operating
during cerebral ischemia [5]. The neuronal nitric oxide
(NO)/Poly ADP ribose (PARP) pathways appear to only
mediate cell death during cerebral ischemia in male
rodents [5]. These sexually divergent pathways may influ-
ence how females and males respond to acute stroke
treatments. For example, PARP inhibitors, and inhibitors
of neuronal NOS are reported to be only neuroprotective
in male mice [5,6]. This concern over sex-related effects
has resulted in recommendations from the Stroke Aca-
demic Industry Roundtable to include female animals
and older animals in pre-clinical testing [7].
The choice of experimental stroke model is also impor-
tant. While the suture occlusion model is often used for
both reperfusion and permanent ischemic models, a
suture is an unnatural occlusion mechanism and reperfu-
sion in human stroke is seldom achieved as abruptly as
removal of the suture in an animal. This abrupt reperfu-
sion may modify the cellular consequences of the ischemic
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human clinical condition [10,11]. Moreover, mechanical
and thrombolytic reperfusions have different profiles and
time courses of cerebral blood flow (CBF) and barrier
damage [12]. It is also important to test adult and older
rodents of both sexes in embolic clot occlusion models
where mostly young male rodents have been used to date.
Minocycline, a tetracycline derivative, is a promising
neuroprotective drug that has reduced infarct size and
improved functional outcomes in multiple experimental
models [13-19]. Recent evide n c es u g g e s t st h a ti ti sa l s o
promising in clinical trials [20,21]. Minocycline inhibits
PARP-1 at nanomolar concentrations, but has multiple
mechanisms of action including inhibition of MMP-9
[14,15,22,23]. However, in a suture occlusion model, min-
ocycline reduced infarct size in male mice, but not in
recently ovariectomized (OVX) female mice [5,24,25]. In
this study we used a new thromboembolic model with
spontaneous reperfusion with a humanized clot. Our aims
were to determine if minocycline was neuroprotective in
an embolic clot model in mice of both sexes and in aged
mice. We also utilized more than 12 weeks interval
between ovariectomy in adult females and embolic stroke
to mimic estrogen homeostasis post-menopause in
humans. A secondary aim was to determine if there was a
sex-specific change in MMP-9 levels.
Materials and methods
Animals
All the experimental procedures have been approved by
the Institutional Animal Care and Use Committee
(IACUC) of Georgia Health Sciences University (GHSU)
in accordance with NIH G u i d ef o rt h eC a r ea n dU s eo f
Laboratory Animals. Wild type C57BL/6J male and female
mice were purchased from the Jackson Laboratory (Bar
Harbor, Maine) and housed in the GHSU Animal Facility
approved by the American Association for Accreditation
of Laboratory Animal Care. Female mice were ovariecto-
mized at 11-12 weeks of age in the Jackson Laboratory
and were about 12 weeks post ovariectomy prior to stroke.
The mean ages of stroked adult animals were: 24.0 ± 4.6
weeks for adult males, 22.9 ± 3.3 weeks for adult females,
and 23.9 ± 2.7 weeks for OVX females. The aged C57BL/6
animals (18.1 ± 0.8 month males and 16.0 ± 1.1 month
females) were from GHSU in-house breeding.
Estrus cycle analysis in mice
Five weeks after ovariectomy female mice (n = 7) were
tested for estrous cyclicity to confirm loss of estrogenic
effect and simulation of postmenopausal stage. The vaginal
smears were compared to cycling adult females (n = 7)
and aged females (n = 5). All vaginal smears were obtained
daily between 9:00 am and 1:00 pm for 8 weeks and
stained with 2% Giemsa solution (Sigma) as described [26].
Estrogen levels
Plasma samples (50 μl) from all post-stroke survived
females and eight randomly selected adult male mice
were used to measure estrogen by enzyme immunoassay
(Cayman Chemical, Ann Arbor, MI).
Preparation of emboli
The method of clot preparation was adapted from ear-
lier reports [10,27] and modified to increase the strength
of uniformity of the fibrin rich core and stability of
occlusion. Briefly, mouse arterial blood was supplemen-
ted with human fibrinogen (2 mg/mL), and immediately
clotted in PE-50 tubing for 6 hours at room temperature
followed by storage at 4°C. Before use, the clot (~5 cm)
was transferred into a modified PE-10 tube filled with
sterile saline and retracted. The clot was then trans-
ferred to a Petri dish containing phosphate-buffered sal-
ine and left for further retraction at room temperature
for 4 hours. A single 9.0 ± 0.5 mm long clot was trans-
ferred to a modified PE-10 catheter for embolization.
Thromboembolic stroke model
Mice were anesthetized with 3.5% isofluorane and main-
tained with 2.0% during the surgery. Body temperature
was maintained at 37°C by a thermo-regulated surgery
pad. By a midline incision on the ventral side of the
neck, the right common carotid artery, the right external
carotid artery (ECA), and the right internal carotid
artery (ICA) were assessed [10]. A modified PE-10
catheter containing a clot was introduced into the ECA
lumen through a small hole, advanced into the ICA, and
the clot was gently injected with 100 μLo ft h es t e r i l e
phosphate-saline buffer (PBS). After thromboemboliza-
tion the catheter was removed immediately. To identify
the location of an embolus after injection, the fibrin-rich
clot was labeled by Evans blue before injection [10]. In
the sham group, an equal volume of PBS without clot
was delivered. Occlusion was confirmed by ≥70% drop
in cerebral blood flow (CBF) compared to the pre-
ischemic value. Animals that showed sustained occlu-
sion were included. The success rate of thromboembolic
MCA occlusion was 95% (208 successes from 219 total
stroked animals) based on changes in CBF. Animals
were randomized immediately after clot injection and
treated with either phosphate saline (PBS, vehicle) or
minocycline (Sigma; 6 mg/kg) via bolus IV injection to
tail vein (0.1 mL/10 g body weight). Sham-operated
mice served as controls.
Regional cortical laser-doppler flowmetry
Cortical laser-Doppler flowmetry ([LDF], Perimed. Inc.)
was performed 30 min and 3 min before occlusion to
record a consistent basal level of peripheral blood flow
in the middle cerebral artery region, and also recorded
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tion was made in the parietal skull (A - P 2 mm, and
lateral 3 mm with respect to bregma) with a low-speed
drill for placement of the LDF probe holder (PH07-6,
Perimed. Inc.). The LDF signal was recorded semi-con-
tinuously and averaged over 10-minute intervals for
each time point.
Neurological assessment
Neurologic deficits in the animals were assessed at 24 hr
post stroke by a 5-point scale scoring: 0, no deficit; 1,
forelimb flexion deficit on contralateral side; 2,
decreased resistance to lateral push and torso turning to
the ipsilateral side when held by tail; 3, very significant
circling to affected side and reduced capability to bear
weight on the affected side; 4, rarely moves sponta-
neously and prefer to stay in rest.
Infarct analysis
Mice were euthanized at 24 hours after stroke for injury
assessment. Brains were perfused with ice cold 0.01 M
phosphate-buffered saline (PBS), cut into 1-mm coronal
slices. Every other slice was stained with 2% 2,3,5-triphe-
nyltetrazolium chloride (TTC, Sigma) for 30 minutes at
37°C, then fixed with 10% formalin in PBS. The images
were digitalized and the infarct volume was analyzed by
software SPOT Advanced (Sterling Heights, MI) as pre-
viously described [14,28,29]. The infarct volumes were
quantified as both direct volume (in mm
3) and indirect
volume (percent volume of the total ischemic hemi-
sphere). The measurement of infarct size was made by
an investigator blinded to treatment group.
Immunoblotting
Six hours after the stroke onset, mice were euthanized,
and brains were perfused with cold phosphate-buffered
saline and extracted. Ischemic hemisphere tissue was
homogenized and lysed in complete Lysis-M EDTA-free
buffer (Roche Diagnostics, Indianapolis, IN). The amount
of total protein was quantified using the EZQ
® Protein
Quantitation Kit (Invitrogen). Samples (30 micrograms of
total protein) were subjected to SDS-PAGE using 10%
NuPAGE
® Novex
® Bis-Tris gels (Invitrogen) and trans-
ferred to 0.2 μm PVDF membranes (Millipore, Billerica,
MA). The membrane was blocked by for non-specific
binding (5% BSA solution), and incubated with polyclo-
nal anti-MMP-9 antibody (G6571, Cell Signaling Tech-
nology, Danvers, MA) at 4°C overnight, followed by
HRP-conjugated donkey anti-rabbit IgG antibody (Jack-
son ImmunoResearch, West Grove, PA). Membranes
were re-probed with mouse monoclonal anti-b-actin
antibody (Sigma-Aldrich Co.) as a loading control. Pro-
teins were visualized with the ECL detection system
(Pierce, Thermo Fisher Scientific) on autoradiography
film (Denville Scientific, Metuchen, NJ). The image was
scanned and processed for densitometric measurement
in Image-J software. The analysis of MMP-9 antigen was
made by an investigator blinded to treatment group.
Gelatin zymography
Basal plasma MMP activity, and at 6 hours after stroke,
was detected using gelatin zymography [14,23,28,29] in
duplicate for each sample. The ischemic hemisphere tissue
was homogenized in 0.05 mol/L Tris buffer (pH 7.4) con-
taining 0.1 mol/L NaCl and 0.17 ng/mL PMSF. Citrated
blood samples were immediately centrifuged at 4000 rpm
for 20 min at 4°C and total plasma protein was determined
with the BCA assay (Pierce). The total lysed basal protein
(100 micrograms) or plasma protein (30 micrograms) was
loaded and separated by a 10% Tris-glycine gel with 0.1%
porcine gelatin (Sigma). The gels were washed with rena-
turing buffer and incubated with developing buffer
(BioRad Labs.) at 37°C for 20 hours. Finally, the gels were
stained with Coomassie blue R-250 followed by appropri-
ate destaining. The gelatinolytic activity of the samples
was assessed by densitometric analysis (Gel-Pro v 3.1,
Media Cybernetics, Carlsbad, CA) of the bands as a rela-
tive comparison to a standard band of recombinant
enzyme. To minimize inter-gel variability, all gels had a
control lane loaded with 0.5 ng recombinant enzyme,
which was used as a standard optical density and enzyme
amount (in ng). The density of the sample bands were
expressed as maximal optical density relative to the stan-
dard band. The analysis of MMP-9 activity was made by
an investigator blinded to treatment group.
Measurement of cerebral perfusion and MRI proce-
dureare described in the Additional Methods.
Statistical analysis
All data are expressed as mean ± SD. Statistical analyses
were performed using SAS
® 9.2 (SAS Institute, Inc.,
Cary, NC). Infarction and neurologic score were ana-
lyzed for males using a 2 Age (adult vs. aged) × 2 TRT
(saline vs. minocycline) ANOVA and for females using a
3 Group (adult, aged, OVX) × 2 TRT (saline vs. minocy-
cline) ANOVA. Adult males and females were compared
using a 2 Sex (male vs. female) × 2 TRT (saline vs. min-
ocycline) ANOVA. MMP-9 antigen and activity levels
were analyzed using a 2 Sex (male vs. OVX) × 3 TRT
(sham, stroke+vehicle, stroke+minocycline) ANOVA. In
all analyses, interactions were tested for possible differ-
ential effects of minocycline treatment on age, sex or
group. Tukey’s multiple comparison tests were used to
compare means for significant main effects. The effect
of minocycline on mortality at 24 hours was analyzed in
adult and aged mice using Fisher’s Exact test. Group
numbers are shown in parentheses. Statistical signifi-
cance was determined at P < 0.05.
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Thromboembolic stroke model
The model was initially optimized using C57BL/6 wild
type male mice (24 ± 4 weeks old, 25 - 30 g) by injecting a
fibrin rich clot formed ex-vivo into the right MCA. Figure
1A represents the brain image with the clot occluding the
ipsilateral MCA origin. The embolization led to consistent
reduction of CBF to 18.1 ± 4.7% of baseline that persisted
(25.4 ± 4.6%) for 6 hours (Figure 1B and Additional file 1,
Figure S1). There was a slow spontaneous CBF restoration
by 24 hours that reached 65 ± 5% from the baseline
as determined by cortical laser-Doppler flowmetry (Figure
1B). Cerebral perfusion imaging with the PeriScan system
yielded similar results (Additional file 2, Figure S2).
Thromboembolic stroke resulted in reproducible infarct
(115 ± 22 mm
3, n = 14) which was confirmed by T2-
weighted MRI (Figure 1C and Additional file 3, Figure S3)
or coronal brain staining with 2,3,5-triphenyltetrazolium
chloride (Figure 1D and Additional file 3, Figure S3). In
this model adult males treated with saline had reliable
injury and low mortality rate at 24 hours (3 out of 17 ani-
mals, Table 1). The model was applied to study the gender
difference in neuroprotection with minocycline using var-
ious subgroups of male (Figure 2) and female (Figure 3)
mice.
Acute minocycline treatment is neuroprotective for male
mice
We tested the neuroprotective efficiency of minocycline in
two different groups of male mice: adult males (24.0 ± 4.6
weeks old) and aged males (18.1 ± 0.8 months old). The
embolization lead to significant and stable drop of CBF in
the MCA territory (18-21% of pre-ischemic values) as
shown in Figures 2A and 2B. However, in adult males the
occlusion was more stable (24% ± 4% of pre-ischemic
values) for 6 hours than in aged group. We observed a
modest spontaneous reperfusion in the aged males (41% ±
9% of pre-ischemic values for 6 hours after occlusion) that
may resulted from the increased endogenous tPA activity
in elderly [30,31]. Animals were randomized immediately
after clot injection and treated with ether PBS (vehicle) or
minocycline (6 mg/kg). Treatment with minocycline did
not significantly affect regional CBF in aged males (Figure
2A), but induced modest spontaneous reperfusion in the
adults (Figure 2B) at 6 hours (48% ± 8% of pre-ischemic
values). Aged males had increased mortality at 24 hours
post stroke that was markedly attenuated after minocy-
cline treatment (Table 1). Minocycline significantly
reduced the infarct volumes (P < 0.0001) and also
improved functional outcomes (p < 0.0001) in surviving
males in both adult and aged groups. Infarct volumes for
adult males were reduced to 18.8% ± 14.5% in minocycline
treated mice versus 43.1% ± 10.6% for the saline group,
and treatment of aged group with minocycline decreased
the infarct volumes to 16.8% ± 8.9% versus 34.6% ± 9.9%
(Figure 4A). Neurologic scores at 24 hours post stroke in
adult males were 2.0 ± 0.8 for the minocycline treated
group versus 3.2 ± 0.6 for the saline group, and 2.0 ± 0.8
versus 3.6 ± 0.5 in the corresponding aged males (Figure
A C D B
Figure 1 Thromboembolic stroke model in C57BL/6 adult male mice. A) The clot is inserted at the MCA origin. Clots were visualized with
Evan’s Blue dye (arrowhead). B) Regional cerebral blood flow (CBF) over time as measured with Laser Doppler flowmetry (means ± SD, n = 7).
The CBF declines to 18 ± 4% of baseline following embolization, which was associated with a reproducible sized infarct of the MCA territory
(115 ± 22 mm
3) at 24 post stroke hours. C, D) Representative infarct area at 24 hours as determined by T2 diffusion-weighted MRI (C) and with
2,3,5-triphenyltetrazolium chloride staining of the coronal brain sections (D). Additional representative images of thromboembolic stroke model
are shown in the Additional file 1 (Figure S1), Additional file 2 (Figure S2), Additional file 3 (Figure S3), Additional file 9 (Additional Figure
Legends) and Additional file 10 (Additional Methods).
Table 1 Mortality rates at 24 hours after stroke
Group Treatment Total in studies, n Dead, n
(mortality rate)
Adult males Vehicle 17 3 (17%)
Minocycline 13 1 (8%)
Aged males Vehicle 17 10 (59%)
Minocycline 9 2 (22%)
Adult females Vehicle 15 2 (13%)
Minocycline 15 3 (20%)
Aged females Vehicle 23 11 (48%)
Minocycline 15 4 (27%)
OVX females Vehicle 26 13 (50%)
Minocycline 15 1 (7%)
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stroke brain are shown in Figures 2A and 2B.
Acute minocycline treatment is neuroprotective for
female mice
To analyze the effect of minocycline on the ischemic
injury in female animals, we studied 3 groups of female
mice: adult females (22.9 ± 3.3 weeks old), aged females
(16.0 ± 1.1 months old), and ovariectomized (OVX)
females (23.9 ± 2.7 weeks old). The age of adult and old
females was selected based on reported time for maxi-
mal and stable cycle frequency (7-10 months) or onset
of acyclicity (13-16 months) in C57BL/6 strain [26].
Consistent with the early report [26], we observed the
cycle regularity in adult females (4-5 days) and signifi-
cantly lengthened cycles in old females (7 - 11 days)
with predomination of diestrus stage. Unlike other stu-
dies [5,24,25], ovariectomy was performed in early age
at least 10 weeks before stroke onset. The estrous cycli-
city test in OVX mice has confirmed their complete acy-
clicity and loss of estrogenic effect.
Consistent with cyclicity data the estrogen levels,
determined at experimental endpoint, were 31.5 ± 51.0
pg/ml for adult females, 13.5 ± 9.5 pg/ml for aged
females, and 6.6 ± 5.3 pg/ml for OVX females (Addi-
tional file 4, Figure S4). Estrogen levels were equivalent
in OVX female mice and adult male mice (6.2 ± 0.7 pg/
ml). All female mice were used regardless of cycle stage
that should reflect the clinical scenario including both
pre- and post menopause females in different estrogen
cycle stages.
The degree of CBF reduction after embolization was
similar among the groups (Figure 3). The degree of
spontaneous CBF restoration was also similar among
the female groups (39% - 51%), but was higher than in
adult males due to possible enhanced endogenous fibri-
nolytic activity in females [32,33]. As expected, adult
-+
Minocycline
A
B
-+
Minocycline
Figure 2 Representative effect of minocycline in adult (A) and
aged (B) males. Coronal TTC sections, outlining the infarct area in
representative subjects treated by the phosphate-saline buffer
(vehicle) or minocycline at 24 hours, are showed in the left panels.
The corresponding change of regional CBF during the first 6 hours
after stroke is showed on the right panel. The value of CBF is
presented as means ± SD.
A
-+
Minocycline
C
-+
Minocycline
B
-+
Minocycline
Figure 3 Representative effect of minocycline in adult (A),
retired (B), and OVX (C) females. Coronal TTC section, outlining
the infarct area in a representative subjects treated by vehicle or
minocycline at 24 hours, are showed on the left panel. The
corresponding change of regional CBF during the first 6 hours after
stroke is showed on right panel. The value of CBF is presented as
means ± SD.
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ischemic injury than males, but this advantage was abol-
ished by aging or lack of estrogen in OVX females (P <
0.001). Mortality rates in the 24 hours studies were sig-
nificantly higher in the aged and OVX groups compared
to adults (P < 0.001, Table). Unlike aged animals, the
mortality in OVX females was associated with intracra-
nial post-stroke bleeding (Additional file 5, Figure S5).
Minocycline treatment provided significant neuroprotec-
tion in all female groups. The mortality rates were
markedly decreased in aged and significantly reduced in
OVX females (P = 0.0061) attenuating bleeding. More-
over, the infarct volumes were reduced (Figure 4B; P <
0.0001) and neurologic scores were also improved (Fig-
ure 5B; P < 0.0001) in all minocycline treated females as
compared to their corresponding vehicle treated
controls.
The inhibition of MMP-9 by minocycline
Because MMP-9 down-regulation has been previously
shown as a potential mechanism of minocycline protec-
tion in young males [14,15], we investigated if minocy-
cline down-regulates MMP-9 in females. All MMP-9
studies were performed by group blinded investigators.
Consistent with previous reports [15] we did not
observe the increase in MMP-9 level in vehicle treated
animals of either group at 24 hours after stroke com-
pared to sham controls (data not shown). In time
dependent studies we detected the maximum MMP-9
level in the brain at 6 hours post stroke (Additional file
6, Figure S6). However, in plasma samples we detected
low, or no, MMP-9 after ischemia compare to sham
controls. This may be associated with using citrate to
prevent blood clotting for plasma harvesting in our
study.
To estimate the gender effect, we used adult males
and OVX females subjected to 6 hours stroke and ran-
domized to sham-control, vehicle and minocycline trea-
ted (ns = 6-8) groups (Table 2). Figure 6A shows that
stroke up-regulated brain level of MMP-9 protein and
minocycline treatment reduced its expression in both
genders (P < 0.0001). The vehicle-treated mice had sig-
nificantly higher levels of MMP-9 protein than sham
operated animals (P = 0.0007) and minocycline treated
animals (P < 0.0001). No statistical difference between
sham and minocycline groups were found (P = 0.77).
Males had significantly higher level of MMP-9 expres-
sion than the OVX females (P = 0.0095). In the vehicle
groups brain MMP-9 activity, as determined by zymo-
graphy was highly variable in both genders (Figure 6B
and Additional file 7, Figure S7). As shown in Addi-
tional file 7 (Figure S7), in a minority of animals acute
ischemia did not result in up-regulation of MMP-9,
such that no significant differences were found for sex
or treatment.
Mortality
Relative to saline, minocycline treatment significantly
reduced mortality at 24 hours post-ischemia for OVX
females (P = 0.006) and for aged mice (54% versus 25%,
P = 0.037) (Table 1). There was not a difference in mor-
tality (P = 1.0) for adult male and female mice (14% ver-
sus 16%). Collapsing across sex and age mortality was
overall reduced in stroked mice with minocycline treat-
ment compared to the non-minocycline controls (16%
vs. 40%).
A ***
Mino     - +        - +
Adult Aged
Mino   - +     - +    - +
Adult Aged OVX
B
***
Males Females
Figure 4 Minocycline reduces brain tissue injury in males (A) and females (B). The infarct size of ischemic MCA territory was estimated as
the percent volume of the total ischemic hemisphere. Regardless of treatment adult females had significantly smaller infarct volumes (both P <
0.0001, ***) than aged and OVX females who were not different than each other (P = 0.77). All data expressed as means ± SD.
Hoda et al. Experimental & Translational Stroke Medicine 2011, 3:16
http://www.etsmjournal.com/content/3/1/16
Page 6 of 10No mortality was observed in the 6 hour study (except
one of the eight males in vehicle group, Table 2).
Discussion
This study has several novel and important findings.
First, we used a thromboembolic clot model rather than
an intraluminal suture model (MCAO). Although
MCAO, as the occlusion-reperfusion model, is widely
utilized, the evolution of infarct within the territory of
blood supplied by MCA is not been well explored [3].
Some study suggests that the fast reperfusion (at suture
removal) may accelerate infarct development and modify
the cellular mechanisms of the ischemic process [3,8,9].
A thromboembolic rodent model better mimics human
stroke and has been previously described. Reperfusion is
gradually and partially restored spontaneously but not
until 6 to 12 hours when the ischemic cascade is already
well advanced. This mimics the clinical scenario where
the clot persists with slow spontaneous reperfusion and
thrombolytic or mechanical reperfusion fails or is not
performed. The model prevents the rapid evolution of
the penumbra (as one of the limitations in clinical neu-
roprotective studies) and allows administration of a neu-
roprotective agent in the ischemic time windows that
are suitable to mimic in clinical trials. Moreover, this
represents the vast majority of human middle cerebral
artery territory strokes (95% of stroke patients) where t-
PA and mechanical removal are not given, or are
ineffective.
Second, in this study we applied the novel approach to
partially “humanize” the stroke mouse model. By supple-
menting the clot with human fibrinogen we adjusted the
physiological level of fibrinogen in mouse blood clot
(1.5 g/L) to the range of human normal value (1.5 - 4 g/
L). This resulted in the increased strength and unifor-
mity of the fibrin-rich clot and stabilized the occlusion.
The stabilization of occlusion for 6 hours in adult males
may be applied for further neuroprotective study beyond
the window of thrombolytic therapy. The “humaniza-
tion” of clot may also partially eliminate the cross spe-
cies restriction barriers for binding of t-PA to the clot
surface.
Third, to the best of our knowledge, this is the first
study that tested minocycline in an thromboembolic
stroke model to investigate gender and age-dependent
influences on stroke injury and outcomes. Our novel
findings provide evidence that minocycline was effective
at reducing infarct size and improving short-term neu-
rological outcome in young male and female mice, OVX
female mice and aged male and female mice.
Overall, analyzing all subgroups and reflecting to the
clinical situation, minocycline reduced mortality (16%
Mino       - +        - +
Adult Aged
A ***
Mino   - +     - +     - +
Adult Aged OVX
B ***
Males Females
Figure 5 Minocycline improves neurologic scores in males (A) and females (A). Neurologic evaluation was performed for surviving animals
at 24 hours. Regardless of treatment adult females had significantly improved neurologic scores (both P < 0.0001, ***) than aged and OVX
females who were not different than each other (P = 0.42). All data expressed as means ± SD.
Table 2 Mortality rates at 6 hours after stroke
Group Treatment Total in studies, n Dead, n
Adult males Vehicle 8 1
Minocycline 7 0
Sham 6 0
OVX females Vehicle 6 0
Minocycline 6 0
Sham 6 0
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32.8 ± 1.7%, P < 0.0001, Additional file 8, Figure S8A)
and improved neurological outcomes (1.9% ± 0.1% vs.
3.2 ± 0.1%, P < 0.0001, Additional file 8, Figure S8B).
Thus, this is the first comprehensive attempt to study
minocycline’s effect by both sex and age. Using the
thromboembolic stroke model we found that minocy-
cline protected not only young adult male but also
female and aged (male & female) brains compared to
control vehicle treatment.
This study is also novel in the context of the revised
preclinical STAIR criteria call for testing of neuropro-
tective agents in female mice and aged mice. Most
experimental stroke studies have been done exclusively
in young male animals, although stroke mainly affects
the elderly. Only a few studies have used female or aged
rats, particularly with an embolic clot model [11,34,35].
Moreover, we could find no comprehensive reports of
the thromboembolic clot model in aged or female mice.
One reason may be the high mortality in this model in
aging animals. In our model we found a mortality of
nearly 50% in both aged females and males and a similar
high mortality in OVX females. Minocycline significantly
reduced this mortality in OVX females and aged mice.
Further studies are needed and planned to determine
the effect of t-PA in the embolic clot model in younger
and older female mice and the expansion of this time
window for minocycline treatment. Including animals of
both sexes and aged animals in an embolic clot model is
warranted for design of future clinical trials.
It is interesting that in MCAO preclinical model min-
ocycline was neuroprotective in male mice but not in
recently OVX females [24]. While minocycline is a
potent PARP inhibitor at nanomolar concentrations
[5,22], minocycline acts by multiple mechanisms of
action [13,14,16,18,19], one of which is MMP-9 inhibi-
tion [14,23]. Activation of MMP-9 plays an important
role in mediating tissue injury during human ischemic
stroke and is associated with ICH after t-PA [36-40].
Suppression of MMP-9 may lead to safer therapeutic
outcomes in acute stroke [41]. Although the different
mechanisms may be responsible for neuroprotection
with minocycline, the difference in stroke models and
f o l l o w i n gi s c h e m i cs e q u e n c e sm a yb et h ek e yf a c t o r so f
attenuation or augmentation of the particular mechan-
ism. Here, we demonstrated that brain MMP-9 was up-
regulated in an embolic model after ischemia in both
male and female mice. Moreover, minocycline reduces
MMP-9 expression for both sexes. MMP-9 activity has
been shown to be up-regulated in the blood and brain
of ischemic rodents, but all studies to date have used
male rodents. MMP-9 activity was highly variable fol-
lowing ischemia in this model and others [15,41] when
t-PA is not given. While there appeared to be a trend
B A ***
Figure 6 Minocycline reduces level of MMP-9 in both genders. A) Densitometric analysis of immunoreactive band intensities and
representative Western Blot showing expression of 92 kDa-MMP-9 in ipsilateral hemispheres of adult male and OVX female mice (n = 6-7
animals per group) at 6 hours after thromboembolization. Values are expressed as relative intensity normalized to 42 kDa-b-actin intensity. The
saline-treated mice had higher levels of MMP-9 than minocycline treated animals (P < 0.0001, ***). Minocycline and sham groups were not
significantly different from each other (P = 0.77). B) Densitometric analysis of brain MMP-9 activity and representative zymography. The brain
injury shows increased variability of MMP-9 activity relative to sham, but there are no sign differences between treatment or sex groups. All data
expressed as means ± SD.
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minocycline treatment we did not detect a significant
overall reduction in activity.
Study limitations
This work presents the proof of principle study to
demonstrate the neuroprotective effect of minocycline
in females using the thromboembolic stroke model. The
study was designed with administration of minocycline
r i g h ta f t e rs t r o k eo n s e ta n das i n g l ee n d p o i n ta t2 4
post-stroke hours, which may limit the translational
potential. However, in light of the novel pre-clinical
model for minocycline evaluation, our data reveal that
minocycline is an efficient neuroprotective agent in
females and aged animals. Further studies are needed to
address later endpoints and neuroprotective pathways of
minocycline.
Conclusions
In summary, the thromboembolic model in mice pro-
vided evidence of neuroprotection with minocycline in
both sexes and in older mice. This model could be used
as a tool for the stroke researcher to design future
experiments in the attempt to translate stroke therapy
in the clinical practice.
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